US009409909B2

(12) **United States Patent**
Charvat et al.

(10) **Patent No.: US 9,409,909 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL) ARYLSULFONAMIDES**

(71) Applicant: **ChemoCentryx, Inc.**, Mountain View, CA (US)

(72) Inventors: **Trevor T. Charvat**, San Jose, CA (US); **Cheng Hu**, Menlo Park, CA (US); **Anita Melikian**, San Francisco, CA (US); **Aaron Novack**, San Jose, CA (US); **Andrew M. K. Pennell**, San Francisco, CA (US); **Edward J. Sullivan**, San Jose, CA (US); **William D. Thomas**, San Jose, CA (US); **Solomon Ungashe**, Fremont, CA (US); **Penglie Zhang**, Foster City, CA (US); **Jay Powers**, Pacific, CA (US); **Sreenivas Punna**, Sunnyvale, CA (US)

(73) Assignee: **ChemoCentryx, Inc.**, Mountain View, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/446,127**

(22) Filed: **Jul. 29, 2014**

(65) **Prior Publication Data**

US 2015/0018337 A1 Jan. 15, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/462,393, filed on May 2, 2012, now Pat. No. 8,835,468, which is a continuation of application No. 12/832,374, filed on Jul. 8, 2010, now Pat. No. 8,198,309, which is a continuation of application No. 12/140,593, filed on Jun. 17, 2008, now Pat. No. 7,776,877.

(60) Provisional application No. 61/046,291, filed on Apr. 18, 2008, provisional application No. 60/948,796, filed on Jul. 10, 2007, provisional application No. 60/945,849, filed on Jun. 22, 2007.

(51) **Int. Cl.**

C07D 213/02	(2006.01)
C07D 473/00	(2006.01)
C07D 209/08	(2006.01)
C07D 231/12	(2006.01)
C07D 231/14	(2006.01)
C07D 231/16	(2006.01)
C07D 231/56	(2006.01)
C07D 233/61	(2006.01)
C07D 235/06	(2006.01)
C07D 235/08	(2006.01)
C07D 249/06	(2006.01)
C07D 249/18	(2006.01)
C07D 401/04	(2006.01)
C07D 401/14	(2006.01)
C07D 403/06	(2006.01)
C07D 413/04	(2006.01)
C07D 413/14	(2006.01)
C07D 417/04	(2006.01)
C07D 471/04	(2006.01)
C07D 487/04	(2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ***C07D 473/00*** (2013.01); ***A61K 31/404*** (2013.01); ***A61K 31/415*** (2013.01); ***A61K 31/4164*** (2013.01); ***A61K 31/4192*** (2013.01); ***A61K 31/437*** (2013.01); ***A61K 31/496*** (2013.01); ***A61K 31/52*** (2013.01); ***A61K 31/5377*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 209/08*** (2013.01); ***C07D 231/12*** (2013.01); ***C07D 231/14*** (2013.01); ***C07D 231/16*** (2013.01); ***C07D 231/56*** (2013.01); ***C07D 233/61*** (2013.01); ***C07D 235/06*** (2013.01); ***C07D 235/08*** (2013.01); ***C07D 249/06*** (2013.01); ***C07D 249/18*** (2013.01); ***C07D 401/04*** (2013.01); ***C07D 401/14*** (2013.01); ***C07D 403/06*** (2013.01); ***C07D 413/04*** (2013.01); ***C07D 413/14*** (2013.01); ***C07D 417/04*** (2013.01); ***C07D 471/04*** (2013.01); ***C07D 487/04*** (2013.01); *C12N 2501/999* (2013.01)

(58) **Field of Classification Search**

CPC C07D 213/02
USPC 546/255
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,817,837	A	6/1974	Rubenstein
3,850,752	A	11/1974	Schuurs et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE	3544409	A1	12/1985
GB	2376691	A	12/2002

(Continued)

OTHER PUBLICATIONS

A. Maquestiau et al., "The Formation of Cyclopentadienone Ions—An Internal Oxidation Process"; *Rapid Communications in Mass Spectrometry*; vol. 3, No. 9; (1989).
Bendele et al., *Arthritis. Rheum.* 42:498-506 (1999).
Bendele et al., *Toxicologic Pathol.* 27:134-142 (1999).
Berge, S.M. et al, "Pharmaceutical Salts", *J. Pharmaceutical Science*, 1977, 66:1-19.
Berman et al., *Immunol. Invest.*, 17:625-677 (1988).

(Continued)

Primary Examiner — Niloofar Rahmani
(74) *Attorney, Agent, or Firm* — Brinks Gilson & Lione; Ryan L. Marshall

(57) **ABSTRACT**

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

14 Claims, No Drawings